Capital Impact Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-1,572
Closed -$179K 136
2021
Q1
$179K Sell
1,572
-24,010
-94% -$3.27M 0.06% 106
2020
Q4
$3.54M Sell
25,582
-25,000
-49% -$2.97M 0.87% 47
2020
Q3
$4.16M Buy
50,582
+20,000
+65% +$1.66M 1.23% 19
2020
Q2
$2.39M Sell
30,582
-15,340
-33% -$1.02M 0.8% 57
2020
Q1
$2.04M Buy
45,922
+1,789
+4% +$92.9K 0.86% 48
2019
Q4
$1.89M Hold
44,133
0.66% 86
2019
Q3
$1.88M Buy
44,133
+7,968
+22% +$433K 0.71% 82
2019
Q2
$2.24M Sell
36,165
-1,693
-4% -$108K 0.82% 33
2019
Q1
$1.58M Hold
37,858
0.7% 65
2018
Q4
$1.58M Buy
37,858
+9,112
+32% +$498K 0.68% 68
2018
Q3
$2.29M Buy
28,746
+1,672
+6% +$136K 0.79% 43
2018
Q2
$2.06M Sell
27,074
-4,917
-15% -$318K 0.76% 44
2018
Q1
$1.63M Buy
+31,991
New +$1.61M 0.67% 65

Other funds holding RARE

Capital Impact Advisors's RARE Position: Q2 2021 in Review

Capital Impact Advisors sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2021, closing a stake of 1,572 shares — an estimated $179K sold.

Capital Impact Advisors first reported a position in RARE in Q1 2018 and held it in 13 quarters. The position peaked at $4.16M in Q3 2020. 241 funds tracked by Wall St. Rank hold RARE as of Q2 2021.

  • Capital Impact Advisors reported no remaining Ultragenyx Pharmaceutical position as of Q2 2021 after selling out during the quarter.
  • Capital Impact Advisors sold 1,572 Ultragenyx Pharmaceutical shares in Q2 2021, an estimated $179K.
  • Capital Impact Advisors first reported a position in Ultragenyx Pharmaceutical in Q1 2018 and held it in 13 quarters.
  • Capital Impact Advisors's Ultragenyx Pharmaceutical position peaked at $4.16M in Q3 2020.
  • 241 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2021.

Based on Capital Impact Advisors's 13F filing for Q2 2021, filed 17 Aug 2021.